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Key points 
 We investigate the underlying molecular defect in a patient who suffers from 
urocanic aciduria presenting with mental retardation and intermittent ataxia. The 
biochemical findings were consistent with a defect in urocanase.  
 We found two putative mutations in the urocanase gene UROC1 that produce 
two amino acid substitutions, p.L70P and p.R450C. In silico predictions, protein 
expression studies and enzyme activity assays suggest that none of the mutations 
produce a fully functional enzyme. The p.L70P substitution, which probably 
imply the disruption of an -helix in the N-terminus, would alter its properties 
and therefore, its function. The p.R450C change would render impossible any 
interaction between urocanase and its substrate and would loss its enzyme 
activity. We therefore suggest that mutations in the UROC1 gene might be the 
cause of the urocanic aciduria in our patient. 
 We found a partial cerebral folate deficiency in this case, that probably lead to a 
impaired pterin and biogenic amines status in cerebrospinal fluid. These findings 
might be explained by the fact that urocanase participates in the synthesis of 
folate metabolites through histidine catabolic pathway. However, low CSF 5-
MTHF concentrations have been related with several genetic and non-genetic 
conditions and consequently, this finding might be also considered unspecific. 
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Abstract  
Urocanase is an enzyme in the histidine pathway encoded by the UROC1 gene. We 
describe the first putative mutations, p.L70P and p.R450C, in the coding region of the 
UROC1 gene in a girl who suffers from urocanic aciduria presenting with mental 
retardation and intermittent ataxia. In silico predictions, protein expression studies and 
enzyme activity assays suggest that none of the mutations can produce a fully functional 
enzyme. The p.L70P substitution, which probably imply the disruption of an -helix in 
the N-terminus, would alter its properties and therefore, its function. The p.R450C 
change would render impossible any interaction between urocanase and its substrate and 
would loss its enzyme activity. Consequently, these studies suggest that both mutations 
could alter the correct activity of urocanase, which would explain the clinical and 
biochemical findings described in the patient. 
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INTRODUCTION 
Three metabolic defects have been recognized in catabolism of histidine: histidase 
(MIM 235800), urocanase (MIM 276860) and glutamate formiminotransferase (MIM 
229100) deficiencies [1,2]. Urocanase deficiency was first reported in 1971 [3], and 
mental retardation was described as the main neurological sign in a single case. Later 
on, two sisters were reported presenting mental retardation plus ataxia and dysarthria 
[4]. In these cases, the defect could be demonstrated by indirect analysis of some 
metabolites of histidine pathway in blood and urine and by the quantification of 
deficient urocanase activity in liver biopsies. By contrast, it has been suggested that 
urocanase deficiency might be a benign condition, as in some healthy cases urocanic 
aciduria was detected by screening analysis [1]. Interestingly, glutamate 
formiminotransferase deficiency, the following biochemical step in histidine 
catabolism, presents some neurological signs common to urocanic aciduria, and 
mutations explaining severe and mild phenotypes have been reported [2]. Here we 
describe a patient presenting urocanic aciduria, mental retardation and intermittent 
ataxia associated with two base-pair changes in the UROC1 gene that produce two 
amino acid substitutions. We argue in favor that these molecular changes may be the 
genetic cause of the clinical and biochemical picture in this patient.  
 
MATERIALS AND METHODS 
Case report 
The patient is a female born of healthy non-consanguineous parents. She presented 
normal development in the first year of life and started to walk alone at 16 months, but 
the parents observed clumsy performance. At 4 years of age, she presented three 
episodes of severe ataxia that lasted 20-25 days, which arose with recurrent infections. 
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These episodes resolved slowly during the next weeks. At 5 years old, she was referred 
for neurological evaluation to our hospital. Clinical examination showed truncal ataxia 
with broad base, ataxic gait, dysmetry more evident on the left arm, action tremor, 
dysartric speech, and normal ocular movements with slight nistagmus on horizontal 
gaze. Normal muscle strength with brisk tendon reflexes and moderate mental 
retardation were also observed. Cranial MRI and neurophysiological studies, including 
electroencephalogram, electroretinogram, visual evoked potentials, brainstem evoked 
potentials, electromyogram, nerve conduction velocities, fundus oculi and cardiological 
examinations, showed normal results. At 9 years of age she presented crises of severe 
ataxia of 20 days duration again. At that moment, she was attending normal school with 
a special program of integration for those with moderate mental retardation. Since then 
she has shown improvement in some neurological signs, such as tremor and ataxia. A 
second cranial MRI-S was normal. She is currently 19. She has slight tremor and 
nistagmus, walks with broad base and has a very clumsy performance. Cognitive 
evaluation shows IQ of 54 (WISC-R: verbal 57 and manipulation 60). 
Routine laboratory analyses were normal including serum amino transferases, 
creatinine, urea and other parameters (no liver or renal dysfunction was detected). 
Screening for inborn errors of metabolism showed normal results, including plasma and 
urine amino acids (no histidine accumulation), blood lactate, sialotransferrin 
isoelectricfocusing, creatine deficiency syndromes, purine and pyrimidine defects and 
organic acidurias. Hypothyroidism and celiac disease were also ruled out. Biochemical 
and/or genetic screening for early onset forms of inherited ataxia showed normal results 
(Friedreich ataxia, ataxia with isolated vitamin E deficiency, ataxia teleangiectasia, 
abetalipoproteinemia, and ataxia of mitochondrial origin). 
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Informed written consent was obtained for biochemical and genetic investigations, 
which were performed following diagnostic protocols approved by the Ethics 
Committee of Hospital Sant Joan de Déu (Barcelona).  
Biochemical analysis 
Urocanic acid in urine was analyzed by HPLC with ultraviolet and diode array detection 
as previously reported [5]. Blood count, serum folate, and plasma total homocysteine 
were determined by standard automated procedures. Cerebrospinal fluid was collected 
according to a standardized protocol, and 5-methyltetrahydrofolate, neopterin, biopterin 
and biogenic amines (5-hydroxyindoleacetic [5-HIAA] and homovanillic acids [HVA]), 
metabolites of serotonin and dopamine, respectively) were determined by HPLC with 
electrochemical and fluorescence detection, as previously reported [6,7].  
Genetic analysis 
Genomic DNA from the propositus and her father was obtained by standard methods 
from peripheral white blood cells. Mutation analysis of the UROC1 gene was performed 
by direct sequencing of PCR products using primers designed according to the reference 
sequence NM_144639 that amplify their twenty exons and intronic flanking sequences 
(Table 1) in an ABI Prism 3130xl autoanalyser (Applied Biosystems, Foster City, CA). 
We investigated in silico the biological relevance of the mutated residues. Conservation 
of residues was analyzed by alignment of related sequences using the program BLAST 
[8]. Secondary structure predictions were calculated with four different software tools 
(GOR, Jpred3, APSSP, and nnPredict), available at ExPASy Proteomics Server 
(http://www.expasy.ch). Sequence-based predictions of the phenotypic consequences of 
the UROC1 p.R450C mutation were proposed using the program SIFT [9]. We also 
predicted the effects of the mutation on the basis of the 3D structure using the 
quantitative rules of Wang and Moult [10], and the PolyPhen server [11]. Visualization 
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of the structure and of the consequences of the UROC1 p.R450C mutation was carried 
out with the program Coot [12]. We used the structure 1UWK [13] (RCBS Protein Data 
Bank) that corresponds to the urocanase from Pseudomona putida in complex with its 
substrate, urocanate.  
Protein production and enzyme activity 
The UROC1 gene (cDNA clone MGC:135008, IMAGE: 40076086) was cloned into the 
expression vector pET100/D-TOPO® (Invitrogen), which allows expression of 
recombinant proteins with an N-terminal tag containing the Xpress epitope and a 
6xHistag. The enzyme was produced in Escherichia coli BL21Start (D3) (Invitrogen). 
The cells were induced with 1 mM IPTG and were grown as previously described [13]. 
The pellet was resuspended in 5 mL of lysis buffer (50 mM potassium phosphate, pH 
7.8, 400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% Triton X-100, 10mM imidazole) 
containing 1 mM phenylmethylsulfonylfluoride (AppliChem) and sonicated. After 
removing the cells debris by centrifugation, the supernatant was applied to a His 
SpinTrap column (GE Healthcare) and eluted according to the manufacturer’s 
instructions. Human UROC1 p.L70P and p.R450C missense mutations were generated 
by PCR with specific primers containing the nucleotide changes and mutated proteins 
were purified as described above for the native urocanase. The fractions containing the 
urocanase (native or any of the mutated variants) were identified by SDS-PAGE and the 
overexpressed bands of the desired proteins were confirmed by western blot using a 
mouse anti-His6 monoclonal antibody (Roche). 
Urocanase was assayed by a previously described spectrophotometric method, in which 
the disappearance of urocanic acid is measured as decrease in absorbance at 277 nm 
[14]. The reaction mixture containing 0.5 mL of 0.2 M potassium phosphate buffer, pH 
7.55, 0.10 mL of 0.01 M EDTA, adjusted to pH 8.0, 0.01 mL of 0.01 M urocanic acid in 
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0.01 N HCl, and water in a total volume of 0.84 mL, was preincubated at 37ºC for 5 
minutes. The reaction was started by adding 0.160 mL of enzyme solution, and the 
decrease in absorbance at 277 nm was monitored for about 15 minutes. The molar 
extinction coefficient of urocanate under these conditions is 18,800 [15]. One unit of 
enzyme is defined as the amount which causes the disappearance of 1 nM of urocanic 
acid per min.  
 
RESULTS 
Urocanic aciduria was demonstrated at different ages (12, 14 and 18 years) with 
urocanis acid levels ranging between 158-202 mmol/mol creatinine (normal values 
below 10 mmol/mol creatinine). Urocanic acid excretion was normal in her father. 
Serum folate was at the lower limit of our reference interval (10 nmol/L: reference 
values 10-26), although neither hyperhomocysteinemia nor megaloblastic anemia was 
observed at any point during the evolution of the disease. Cerebrospinal fluid results are 
reported in Table 2. 5-methyltetrahydrofolate, neopterin and biopterin deficiencies were 
observed together with an evident reduction in homovanillic acid and HVA/5-HIAA 
ratio. Other parameters determined in cerebrospinal fluid, such as glucose, proteins, 
cells and amino acids were normal.  
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Table 1. PCR primers used for mutation screening of the UROC1 gene 
Exon Primers 
1 UROC_E1D: 5’-aatgagaggctggaggagg-3’ UROC_E1R: 5’-gtgctcactatggaccacc-3’ 
2 UROC_E2D: 5’- agacaaatccatttgggagg-3’ UROC_E2R: 5’- gtccctttgaagctgtacc-3’ 
3 UROC_E3D: 5’- ggctagatgctgtgctttgg-3’ UROC_E3R: 5’-tcgtgttctgtttctgctgg -3’ 
4 UROC_E4D: 5’- ctctccctgtctgcaactcc-3’ UROC_E4R: 5’-ccacacaatctccaatgctgg -3’ 
5+6 UROC_E5-6D: 5’- ggtgctgcttctgttgacag -3’ UROC_E5-6R: 5’- atggctaacggggaaacacg-3’ 
7+8 UROC_E7-8D: 5’- agtggctgggaggacctgg -3’ UROC_E7-8R: 5’- ggtgtaagtgatccgggagg-3’  
9 UROC_E9D: 5’- acctacaggggatgacacc -3’ UROC_E9R: 5’- aaacaggcccacaccaagc-3’ 
10+11 UROC_E10-11D: 5’- tgtgtctggggcacctatgc -3’ UROC_E10-11R: 5’- aactaggtggtggccagagc-3’ 
12 UROC_E12D: 5’- actgagggtgccacattggg-3’ UROC_E12R: 5’- aagcctcggtcaggatttgc-3’ 
13 UROC_E13D: 5’- aagaccttgtgcatccttcc -3’ UROC_E13R: 5’- gcttctccaacctaaataccc-3’ 
14 UROC_E14D: 5’- cacctgacttctggatgctg-3’ UROC_E14R: 5’- gtctctatggaggcagaagc-3’ 
15 UROC_E15D: 5’- ccctcaccttgtgtcctagc -3’ UROC_E15R: 5’-ttgggcagtcttctgacagc -3’ 
16 UROC_E16D: 5’- accccaggtcctgttattgc -3’ UROC_E16R: 5’-ggaagaggctgagggatgc -3’ 
17 UROC_E17D: 5’-cccttgtcctcagtctttacc -3’ UROC_E17R: 5’- cactctatgccgagcctctc -3’ 
18 UROC_E18D: 5’- acgactgctgctgtgagagg -3’ UROC_E18R: 5’- cccaaaacttccacatcagcc-3’ 
19 UROC_E19D: 5’- tccaaaacatgggcttctgc -3’ UROC_E19R: 5’- tgtggtcatgagaggaatcc-3’ 
20 UROC_E20D: 5’- gcccggttatgttgacatgg -3’ UROC_E20R: 5’- gcgagaagtgcaggtagtgc-3’ 
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Table 2. Main biochemical features of the patient in cerebrospinal fluid*. 
 
 Patient Reference values 
5-methyltetrahydrofolate 
Neopterin 
Biopterin 
5-hydroxyindoleacetic acid 
Homovanillic acid 
HVA/5-HIAA ratio 
36 
9 
10 
93 
90 
0.98 
42 – 81 nmol/L 
11 – 24 nmol/L 
14 – 36 nmol/L 
63 – 185 nmol/L 
124 – 362 nmol/L 
1.50 – 3.50 
 
* In the patient, cerebrospinal fluid was collected at 18 years of age. Results 
were compared with reference ranges established in our laboratory in a control 
population of similar age (n = 15; age range: 16 to 20 years). 
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Persistent urocanic aciduria and clinical data, mainly mental retardation, pointed 
towards a diagnosis of urocanase deficiency. Analysis of the UROC1 gene revealed that 
the patient harbored two nucleotide changes, c.209T>C in exon 2 and c.1348C>T in 
exon 14 (Figure 1). These base-pair changes are translated in two amino acid changes, 
p.L70P and p.R450C, respectively. Moreover, sequencing analysis showed the neutral 
change c.1056C>T (p.G352G) in exon 11 previously described as a SNP, rs 34025926, 
(http://www.ncbi.nlm.nih.gov/SNP). The proband’s father was heterozygous carrier of 
the p.R450C mutation (no DNA was available from the mother). Both nucleotide 
changes were searched in 200 chromosomes from healthy controls of Spanish ancestry 
by automated sequencing, and neither of them was detected, suggesting that they could 
be pathogenic mutations. Then, we proceeded to perform a phylogenetic analysis of the 
L70 and R450 residues. Leucine at position 70 was present in, besides Homo sapiens, 
some mammals (Canis familiaris, Equus caballus, Monodelphis domestica, Bos taurus 
and Macaca mulatta) and in Gallus gallus. The secondary structure predicted for the 
human urocanase showed that an -helix was always predicted from residue 63 to 
residue 70.With respect to arginine 450, the alignment of the urocanase sequences 
revealed that R450 is extremely conserved and in fact no variation was found in more 
than one hundred aligned sequences from different organisms (data available on 
request). The p.R450C mutation was always predicted as a probably pathologic change 
by four software programs. In P. putida, the orthologue residue of human R450 is R362 
which has capital importance for the enzymatic activity of the urocanase. Urocanate is 
tightly bound to urocanase by means of its carboxylate group, forming a buried salt-
bridge with R362 [13]. If this arginine is mutated to cysteine, the urocanase would lose 
this interaction and would therefore be unable to bind the urocanate (Figure 2). 
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The protein expression analysis by SDS-PAGE, after sonication and previous to 
purification, revealed that both the native and the p.R450C urocanase were present in 
the supernatant and the pellet fractions (Figure 3A & 3B). However, the p.L70P form 
was only detected in the pellet (Figure 3C). To optimize protein expression in bacteria, 
we performed experiments of the p.L70P mutant under different conditions of IPTG 
concentration, temperature and inducing time. In any case we could not obtain the 
p.L70P protein in the supernatant (Figure 3C). Thus, purification and enzymatic assays 
were only performed for the native protein and the p.R450C mutant. The 
spectrophotometric enzymatic assay showed that the native urocanase had a specific 
activity of approximately 70 units per mg of protein. By contrast, the p.R450C 
urocanase lacked of detectable activity.  
 
 
DISCUSSION 
We describe two nucleotide substitutions in the coding region of the UROC1 gene in a 
girl who suffers from urocanic aciduria, with mental retardation and intermittent ataxia 
as the main symptoms. The propositus is a compound heterozygote for the UROC1 
p.L70P/p.R450C mutations. In silico analyses of the putative structure of human 
urocanase revealed that both amino acid substitutions could have a pathological effect. 
The L70 residue is only conserved in a few mammals and in Gallus gallus. Lower 
organisms such as P. putida lack it, making impossible to analyze the consequences of 
this mutation in the available structures of the urocanase (RCBS Protein Data Bank). 
The predicted secondary structure using the human urocanase sequence as a template 
however, suggested that the L70 residue could form part of an -helix, and then the 
change to proline may disrupt the -helix, possibly resulting in an alteration of the 
structure of the N-terminal region. The normal function of the enzyme therefore would 
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be altered. We could not perform an enzyme activity assay for the p.L70P protein 
because this mutant protein was not obtained in the soluble fraction. The p.L70P protein 
was only observed in the precipitate. According to the in silico analysis, this mutation 
would produce a conformational change of -helix at the N-terminus. The putative 
abnormal conformation could affect the solubility of the enzyme and the correct enzyme 
function. The p.R450C mutation affects an extremely conserved residue and no change 
could be tolerated in this position according to in silico analyses. Because of the 
predictable interaction by a salt-bridge between the R450 in the human urocanase and 
its substrate, urocanate, according to the structure of P. putida [13], the substitution of 
R450 by a cysteine would imply that urocanase could not interact with urocanate. That 
is why an enzyme with the p.R450C mutation would not be able to metabolize 
urocanate and, therefore, the enzyme would be deficient and then urocanic acid 
accumulates and excretes in urine in large amounts. In fact, enzyme activity was not 
detectable in the p.R450C urocanase purified extracts from the bacterial expression 
system whereas that the native urocanase had a specific activity of approximately 70 
units per mg of protein. Moreover, neither of these two changes has been identified in 
200 control chromosomes, providing additional support for the view that these 
nucleotide changes do not represent polymorphisms and may be the causative 
pathogenic mutations. Consequently, in silico predictions, protein studies and enzyme 
activity assays would suggest that none of the mutations, p.L70P and p.R450C, in 
urocanase could produce a fully functional enzyme.  
The healthy father of the patient is a carrier in heterozygosis of the UROC1 p.R450C 
mutation. This finding would indicate that the urocanase deficiency is a hereditary 
disease. To date, four symptomatic children with urocanic aciduria have been reported: 
two isolated cases [3,16], and two affected sisters [4]. With regard to the two-sisters 
  
14
 
 
 
 
 
family previous generations were also possibly affected, which would suggest 
autosomal dominant inheritance. The genetic analysis performed in the propositus and 
in her father allows us to conclude that the urocanase deficiency seems to be a genetic 
disorder with autosomal recessive inheritance. The other defects of the histidine 
catabolism, histidase and glutamate formiminotransferase deficiencies, are also 
autosomal recessive disorders.  
The propositus suffers from urocanic aciduria presenting mental retardation and ataxia, 
and also tremor and nistagmus. These latter neurological signs have not previously been 
associated with urocanase deficiency [1,3,4]. Histidine catabolism comprises several 
metabolic steps leading to the synthesis of 5-10-methenyltetrahydrofolate, a precursor 
of the purine ring and other folate metabolites. Although the biosynthesis of folate 
derivatives through histidine catabolism might represent a minor source of single carbon 
units [17], we found low-normal blood folate together with decreased CSF 5-MTHF 
values in our case. As previously reported for other folate metabolism disturbances 
[18,19], we also found an association between decreased folate values in CSF, pterin 
deficiencies and decreased values of HVA, the main metabolite of dopamine. In this 
sense, tremor and probably other neurological signs might be related with dopamine 
deficiency. Furthermore, symptoms such as ataxia and psychomotor retardation have 
commonly been observed among patients with cerebral folate deficiency, even those 
with very slight cerebral folate deficiency [20]. However, low CSF 5-MTHF 
concentrations has been related with several genetic and non-genetic conditions [17, 
18], and consequently, this finding might be also considered unspecific. 
It has been demonstrated that patients with glutamate formiminotransferase deficiency 
also suffer from mental and physical retardation, which reinforces the hypothesis that a 
severe metabolic blockade in urocanic acid catabolism might cause the clinical 
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phenotype. An explanation for differing phenotypes among patients with urocanic 
aciduria might be similar to that suggested for glutamate formiminotransferase 
deficiency [2], and factors such as severity of mutations, amount of accumulated 
urocanic acid, impaired central nervous system folate, pterins and dopamine status and 
other unknown factors might be involved. Urocanic acid has been related with skin 
photoprotection and regulation of immune response [21,22], although no immune 
alterations or skin abnormalities were observed in our case. The precise implication of 
urocanic acid accumulation in the clinical phenotype therefore will require further 
investigation. 
In conclusion, we suggest that mutations in the UROC1 gene might be the cause of the 
urocanic aciduria in our patient. In spite of we cannot demonstrate a definite causative 
relationship of UROC1 mutations and the mental and neurological syndrome in this 
patient, we propose that mutational analysis of the urocanase gene is advisable in this 
rare condition, along with evaluation of folate deficiency consequences in central 
nervous system, such as pterin and dopamine status or other biological markers of 
impaired folate status.  
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Figure 1. Electrophoregrams of the two identified mutations in the UROC1 gene. (A) 
the c.209T>C mutation and (B) the c.1348C>T mutation, both in heterozygosis, in a 
healthy control and in the proband. Black arrows indicate the changes. (C) Alignment of 
the urocanase from Homo sapiens, Canis familiaris, Mus musculus and Pseudomona 
putida. Above, the L70 amino acid is only conserved in some mammals and in Gallus 
gallus and, Pseudomona putida lacks of this residue. Below, the R450 amino acid is 
perfectly conserved across all the analyzed species. 
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Figure 2. Visualization of the effect that the p.R450C mutation causes in the urocanase. 
Figure shows the structure 1UWK from Pseudomona putida in complex with its 
substrate, urocanate, using the program Coot. On the left, the native structure. On the 
right, the R362 is changed to C362 and therefore, the salt/bridge between this residue 
and the substrate is lost. In P. putida the orthologue of the human R450 residue is the 
R362 amino acid.  
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Figure 3. Visualization of the native urocanase and the mutated variants, p.R450C and 
p.L70P. The BL21StarTM (D3) cells overexpressing the native and mutated urocanase 
were sonicated and centrifugated obtaining its insoluble and soluble fractions. The 
soluble fraction was applied into a His SpinTrapTM column and two fractions were 
separated, retained (R.) and non-retained (N.R.). The retained fractions were eluted and 
contained the purified proteins. All obtained fractions were visualized by Coomassie 
Stain SDS-PAGE gel. The black arrows indicate the bands corresponding to (A) the 
native urocanase and (B) the p.R450C mutant, and the arrow head shows (C) the p.L70P 
mutant. Figure shows that similar amounts of purified protein were obtained for the 
native urocanase and the p.R450C mutant. By contrast, the p.L70P protein was only 
present in the pellet (insoluble fraction). “M” is the molecular weight marker 
SeeBluePlus2 Pre-Stained Standard (Invitrogen). The estimated molecular weight of 
urocanase is aproximately 74.8 KDa. 
 
 
